Overcoming the challenges of implementing serialization across a diverse pharmaceutical manufacturing environment
New Webinar Hosted by Xtalks.
As the EU and US deadlines for serialization loom closer, companies are beginning to wake up to the benefits of track and trace. However, for the average pharmaceutical company, trying to focus on core business, while also keeping track of new regulations and timelines is an almost impossible task even within major markets.
In this webinar, the challenges of serialization implementation will be examined by a panel of industry experts from GSK, Zenith Technologies, and SEA Vision. The live broadcast takes place on Tuesday, 20 September 2016 at 10:30 am EDT (3:30 pm BST/UK).
How important was it to find the right serialization partner and what should one look for when selecting a partner?
What considerations need to be made regarding deployment and implementation?
What is the biggest challenge after the project goes live?
How important is education and communication in driving the cultural change across the business?
How pivotal is continuous training in the successful operation of serialization across diverse locations?
This industry driven presentation will focus on how a pharmaceutical company should design a solution to meet the market requirements and regulations of serialization. Sea Vision then take delegates through packaging line equipment through to enterprise level, taking a deep dive into the technology behind serialization. The presentation will look at the main areas of design, build, deploy and support with a reference to a real life case study example of global deployment.
The presenters will take the audience through 14 steps of a best practice serialization solution using their expertise from having implemented serialization across global sites. This will include looking at access and design, build, deployment and support considerations, plus tips and advice for the audience.
A live Q&A with the audience will be included at the end of the presentation.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.